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ABSTRACT 
 
 
Introduction: Dipeptidyl Peptidase 4 Inhibitor (DPP4-I) is a relatively new 
antidiabetic agent, hence the study on glycemic outcome in Malaysian population is 
still lacking. Currently, there is no study conducted in Putrajaya Hospital to examine 
the outcome of DPP4-I and its combination on glycemic control of Type 2 Diabetes 
Mellitus (T2DM) patients, response towards DPP4-I and predictors for HbA1c 
reduction. Objective: To evaluate outcome at week 16, 32 and 52; to determine ADR 
arises from DPP4-I; and to evaluate predictors for HbA1c reduction at week 52. 
Method: A retrospective observational study was conducted on 184 T2DM patients 
that were prescribed with DPP4-I. Paired t-test, ANOVA and linear regression 
analysis were conducted accordingly. Results: 39.1% of study subjects managed to 
attain HbA1c value ≤7.0% after 52 weeks of therapy with DPP4-I and its 
combinations. The mean HbA1c reduction was 0.7% compared to baseline. 70.7% 
were responsive to the DPP4-I treatment with age at the initiation of DPP4-I, mean 
HbA1c at baseline and week 52 and mean number of antidiabetics prescribed at 
baseline and week 52 were significantly different between subgroups. Unresponsive 
subgroup attained only 0.2% HbA1c reduction at around week 16 compared to 
significant HbA1c reduction attained by responsive group. 2.7% adverse drug reaction 
related to DPP4-I was reported. Baseline HbA1c values, HbA1c changes at around 
week 16 and age were found to be the predictors for HbA1c reduction. Conclusion: 
The addition of DPP4-I demonstrated moderate glycemic reduction to T2DM patients. 
However, factors such as adherence towards antidiabetics, diet, physical activity and 
insulin intensification that was not assessed in this study may also influence this 
effect.  
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